Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vera Therapeutics, Inc.VERA · Entity 4358 | Director · PRESIDENT AND CEO | September 15, 2026 | September 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vera Therapeutics, Inc.
Report date September 15, 2026 · Filed September 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 235,244 |
Ending reported balance
After 2026-09-15 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-15 · Exercise / conversion · Acquired 18,500 · Balance 253,744 Row 2 · 2026-09-15 · Sale · Disposed 18,500 · Balance 235,244 F1: The sales were made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.90 · Expires 2030-12-15 | Direct | 488,801 |
Reported balance
After 2026-09-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-15 · Exercise / conversion · Disposed 18,500 · Balance 488,801 F2: 1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vested monthly thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales were made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
F2: 1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vested monthly thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 25, 2024 Filed Sep 27, 2024 20:05 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 8,643 | $2.90 | $25,037.04 |
DisclosureSEC source: 0001415889-24-024033 · form4-09272024_080904.xml · nonDerivative · entry 1 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 316,615 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 11, 2024 Filed Sep 13, 2024 20:36 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,625 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001415889-24-023372 · form4-09132024_080943.xml · derivative · entry 5 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 827,337 Underlying: Class A Common Stock · 15,625 shares Expires 2030-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| September 11, 2024 Filed Sep 13, 2024 20:36 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 6,351 | $37.78 | $239,910.93 |
DisclosureSEC source: 0001415889-24-023372 · form4-09132024_080943.xml · nonDerivative · entry 4 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 307,972 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 23, 2024. F3 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $37.60 to $38.06, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 11, 2024 Filed Sep 13, 2024 20:36 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 6,351 | $2.90 | $18,397.58 |
DisclosureSEC source: 0001415889-24-023372 · form4-09132024_080943.xml · nonDerivative · entry 3 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 314,323 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 11, 2024 Filed Sep 13, 2024 20:36 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 9,274 | $37.31 | $346,023.14 |
DisclosureSEC source: 0001415889-24-023372 · form4-09132024_080943.xml · nonDerivative · entry 2 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 307,972 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 23, 2024. F2 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $36.60 to $37.59, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 11, 2024 Filed Sep 13, 2024 20:36 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 9,274 | $2.90 | $26,864.92 |
DisclosureSEC source: 0001415889-24-023372 · form4-09132024_080943.xml · nonDerivative · entry 1 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 317,246 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 28, 2024 Filed Aug 30, 2024 20:04 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,625 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001415889-24-022620 · form4-08302024_080840.xml · derivative · entry 7 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 842,962 Underlying: Class A Common Stock · 15,625 shares Expires 2030-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| August 28, 2024 Filed Aug 30, 2024 20:04 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 700 | $37.53 | $26,270.02 |
DisclosureSEC source: 0001415889-24-022620 · form4-08302024_080840.xml · nonDerivative · entry 6 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 307,972 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 23, 2024. F5 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $37.50 to $37.61, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 28, 2024 Filed Aug 30, 2024 20:04 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 13,995 | $36.82 | $515,353.28 |
DisclosureSEC source: 0001415889-24-022620 · form4-08302024_080840.xml · nonDerivative · entry 5 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 308,672 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 23, 2024. F4 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $36.46 to $37.44, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 28, 2024 Filed Aug 30, 2024 20:04 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 700 | $37.54 | $26,274.99 |
DisclosureSEC source: 0001415889-24-022620 · form4-08302024_080840.xml · nonDerivative · entry 4 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 322,667 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 23, 2024. F3 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $37.50 to $37.59, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 28, 2024 Filed Aug 30, 2024 20:04 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 700 | $2.90 | $2,027.76 |
DisclosureSEC source: 0001415889-24-022620 · form4-08302024_080840.xml · nonDerivative · entry 3 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 323,367 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 28, 2024 Filed Aug 30, 2024 20:04 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 14,925 | $36.80 | $549,241.49 |
DisclosureSEC source: 0001415889-24-022620 · form4-08302024_080840.xml · nonDerivative · entry 2 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 322,667 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 23, 2024. F2 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $36.46 to $37.42, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 28, 2024 Filed Aug 30, 2024 20:04 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 14,925 | $2.90 | $43,234.74 |
DisclosureSEC source: 0001415889-24-022620 · form4-08302024_080840.xml · nonDerivative · entry 1 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 337,592 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 21, 2024 Filed Aug 23, 2024 21:40 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 14,471 | $39.76 | $575,424.84 |
DisclosureSEC source: 0001415889-24-022150 · form4-08232024_090800.xml · nonDerivative · entry 1 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 322,667 F1 · kind: Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units pursuant to an election intended to satisfy the conditions of Rule 10b5-1(c) made by the Reporting Person on August 26, 2022. F2 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $38.95 to $40.73, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 14, 2024 Filed Aug 16, 2024 20:31 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,625 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001415889-24-021460 · form4-08162024_080827.xml · derivative · entry 3 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 858,587 Underlying: Class A Common Stock · 15,625 shares Expires 2030-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| August 14, 2024 Filed Aug 16, 2024 20:31 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 15,625 | $37.56 | $586,926.56 |
DisclosureSEC source: 0001415889-24-021460 · form4-08162024_080827.xml · nonDerivative · entry 2 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 337,138 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 23, 2024. F3 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $37.01 to $37.97, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 14, 2024 Filed Aug 16, 2024 20:31 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 15,625 | $2.90 | $45,262.50 |
DisclosureSEC source: 0001415889-24-021460 · form4-08162024_080827.xml · nonDerivative · entry 1 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 352,763 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,511 shares of Class A Common Stock acquired under the Issuer's 2021 Employee Stock Purchase Plan on March 13, 2024. Read SEC document |
| January 16, 2024 Filed Jan 18, 2024 21:54 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | GrantStock Option (right to buy) · Derivative | 292,500 | $0.00 Strike: $16.80 | $0.00 |
DisclosureSEC source: 0001415889-24-001526 · form4-01182024_090156.xml · derivative · entry 2 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 292,500 Underlying: Class A Common Stock · 292,500 shares Expires 2034-01-15 F2 · derivative.exercise_date: 1/48 of the shares subject to the stock option will vest and become exercisable on February 16, 2024, and 1/48th of the shares subject to the stock option will vest and become exercisable monthly on the same day of each month thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| January 16, 2024 Filed Jan 18, 2024 21:54 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | GrantClass A Common Stock | 78,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-001526 · form4-01182024_090156.xml · nonDerivative · entry 1 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 335,627 F1 · shares: Represents the number of shares of Class A Common Stock underlying the restricted stock units ("RSUs") under the Issuer's 2021 Equity Incentive Plan. One-fourth of the RSUs, rounded to the nearest whole share, vest on each of February 20, 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| December 29, 2023 Filed Jan 3, 2024 21:15 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionStock Option (Right to Buy) · Derivative | 13,000 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001209191-24-000352 · doc4.xml · derivative · entry 4 Fordyce Marshall · CIK 0001859453 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 874,212 Underlying: Class A Common Stock · 13,000 shares Expires 2030-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| December 29, 2023 Filed Jan 3, 2024 21:15 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionStock Option (Right to Buy) · Derivative | 516 | $0.00 Strike: $2.32 | $0.00 |
DisclosureSEC source: 0001209191-24-000352 · doc4.xml · derivative · entry 3 Fordyce Marshall · CIK 0001859453 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 516 shares Expires 2030-01-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/3 of the shares subject to the option vested on January 10, 2021, and 1/36 of the shares vest monthly thereafter. Read SEC document |
| December 29, 2023 Filed Jan 3, 2024 21:15 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 13,000 | $2.90 | $37,658.40 |
DisclosureSEC source: 0001209191-24-000352 · doc4.xml · nonDerivative · entry 2 Fordyce Marshall · CIK 0001859453 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 256,877 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 29, 2023 Filed Jan 3, 2024 21:15 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 516 | $2.32 | $1,195.78 |
DisclosureSEC source: 0001209191-24-000352 · doc4.xml · nonDerivative · entry 1 Fordyce Marshall · CIK 0001859453 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 243,877 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 21, 2023 Filed Aug 23, 2023 21:56 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 5,210 | $16.66 | $86,778.80 |
DisclosureSEC source: 0001209191-23-047102 · doc4.xml · nonDerivative · entry 1 Fordyce Marshall · CIK 0001859453 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 243,361 F1 · kind: Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units pursuant to an election intended to satisfy the conditions of Rule 10b5-1(c) made by the Reporting Person on August 26, 2022. F2 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $16.65 to $16.893, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes shares acquired under the Issuer's Employee Stock Purchase Plan on September 13, 2022 for 1,085 shares, and on March 13, 2023 for 1,183 shares. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 21:05 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | GrantStock Option (right to buy) · Derivative | 450,000 | $0.00 Strike: $7.87 | $0.00 |
DisclosureSEC source: 0001209191-23-010491 · doc4.xml · derivative · entry 1 Fordyce Marshall · CIK 0001859453 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,000 Underlying: Class A Common Stock · 450,000 shares Expires 2033-02-14 F1 · derivative.exercise_date: 1/48 of the total stock option will vest and become exercisable monthly on the same day of each month following February 15, 2023, subject to continuous service of the Reporting Person on each vesting date. Read SEC document |
| November 16, 2022 Filed Nov 17, 2022 21:06 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001209191-22-057513 · doc4.xml · derivative · entry 4 Fordyce Marshall · CIK 0001859453 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 887,212 Underlying: Class A Common Stock · 60,000 shares Expires 2030-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| November 16, 2022 Filed Nov 17, 2022 21:06 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,153 | $0.00 Strike: $2.32 | $0.00 |
DisclosureSEC source: 0001209191-22-057513 · doc4.xml · derivative · entry 3 Fordyce Marshall · CIK 0001859453 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 516 Underlying: Class A Common Stock · 5,153 shares Expires 2030-01-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/3 of the shares subject to the option vested on January 10, 2021, and 1/36 of the shares vest monthly thereafter. Read SEC document |
| November 16, 2022 Filed Nov 17, 2022 21:06 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 60,000 | $2.90 | $173,808.00 |
DisclosureSEC source: 0001209191-22-057513 · doc4.xml · nonDerivative · entry 2 Fordyce Marshall · CIK 0001859453 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,303 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 16, 2022 Filed Nov 17, 2022 21:06 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 5,153 | $2.32 | $11,941.56 |
DisclosureSEC source: 0001209191-22-057513 · doc4.xml · nonDerivative · entry 1 Fordyce Marshall · CIK 0001859453 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,303 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 04, 2022 Filed Oct 5, 2022 20:05 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionStock Option (Right to Buy) · Derivative | 18,223 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001209191-22-052719 · doc4.xml · derivative · entry 12 Fordyce Marshall · CIK 0001859453 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 947,212 Underlying: Class A Common Stock · 18,223 shares Expires 2030-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: 1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| October 04, 2022 Filed Oct 5, 2022 20:05 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 906 | $22.19 | $20,100.79 |
DisclosureSEC source: 0001209191-22-052719 · doc4.xml · nonDerivative · entry 10 Fordyce Marshall · CIK 0001859453 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,150 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 9, 2022. F6 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $22.08 to $22.35, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 04, 2022 Filed Oct 5, 2022 20:05 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 906 | $2.90 | $2,624.50 |
DisclosureSEC source: 0001209191-22-052719 · doc4.xml · nonDerivative · entry 9 Fordyce Marshall · CIK 0001859453 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,056 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 04, 2022 Filed Oct 5, 2022 20:05 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 10,418 | $21.69 | $225,993.51 |
DisclosureSEC source: 0001209191-22-052719 · doc4.xml · nonDerivative · entry 8 Fordyce Marshall · CIK 0001859453 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,150 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 9, 2022. F5 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $21.07 to $22.04, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 04, 2022 Filed Oct 5, 2022 20:05 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 10,418 | $2.90 | $30,178.86 |
DisclosureSEC source: 0001209191-22-052719 · doc4.xml · nonDerivative · entry 7 Fordyce Marshall · CIK 0001859453 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,568 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 04, 2022 Filed Oct 5, 2022 20:05 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 6,899 | $20.29 | $139,971.05 |
DisclosureSEC source: 0001209191-22-052719 · doc4.xml · nonDerivative · entry 6 Fordyce Marshall · CIK 0001859453 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,150 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 9, 2022. F4 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $20.03 to $20.99, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 04, 2022 Filed Oct 5, 2022 20:05 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 6,899 | $2.90 | $19,985.02 |
DisclosureSEC source: 0001209191-22-052719 · doc4.xml · nonDerivative · entry 5 Fordyce Marshall · CIK 0001859453 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,049 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 20:05 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionStock Option (Right to Buy) · Derivative | 13,777 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001209191-22-052719 · doc4.xml · derivative · entry 11 Fordyce Marshall · CIK 0001859453 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 965,435 Underlying: Class A Common Stock · 13,777 shares Expires 2030-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: 1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 20:05 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 2,408 | $21.16 | $50,950.87 |
DisclosureSEC source: 0001209191-22-052719 · doc4.xml · nonDerivative · entry 4 Fordyce Marshall · CIK 0001859453 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,150 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 9, 2022. F3 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $21.00 to $21.35, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 20:05 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 2,408 | $2.90 | $6,975.49 |
DisclosureSEC source: 0001209191-22-052719 · doc4.xml · nonDerivative · entry 3 Fordyce Marshall · CIK 0001859453 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,558 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 20:05 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 11,369 | $20.39 | $231,757.07 |
DisclosureSEC source: 0001209191-22-052719 · doc4.xml · nonDerivative · entry 2 Fordyce Marshall · CIK 0001859453 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,150 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 9, 2022. F2 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.97, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 20:05 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 11,369 | $2.90 | $32,933.72 |
DisclosureSEC source: 0001209191-22-052719 · doc4.xml · nonDerivative · entry 1 Fordyce Marshall · CIK 0001859453 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,519 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 13, 2022 Filed Sep 14, 2022 20:12 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionStock Option (Right to Buy) · Derivative | 22,363 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001209191-22-049902 · doc4.xml · derivative · entry 5 Fordyce Marshall · CIK 0001859453 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 979,212 Underlying: Class A Common Stock · 22,363 shares Expires 2030-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| September 13, 2022 Filed Sep 14, 2022 20:12 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 12,200 | $21.48 | $262,008.42 |
DisclosureSEC source: 0001209191-22-049902 · doc4.xml · nonDerivative · entry 4 Fordyce Marshall · CIK 0001859453 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,150 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 9, 2022. F3 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $21.13 to $22.05, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 13, 2022 Filed Sep 14, 2022 20:12 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 12,200 | $2.90 | $35,340.96 |
DisclosureSEC source: 0001209191-22-049902 · doc4.xml · nonDerivative · entry 3 Fordyce Marshall · CIK 0001859453 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,350 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 13, 2022 Filed Sep 14, 2022 20:12 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 10,163 | $20.78 | $211,227.79 |
DisclosureSEC source: 0001209191-22-049902 · doc4.xml · nonDerivative · entry 2 Fordyce Marshall · CIK 0001859453 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,150 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 9, 2022. F2 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $20.12 to $21.11, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 13, 2022 Filed Sep 14, 2022 20:12 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 10,163 | $2.90 | $29,440.18 |
DisclosureSEC source: 0001209191-22-049902 · doc4.xml · nonDerivative · entry 1 Fordyce Marshall · CIK 0001859453 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,313 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 12, 2022 Filed Sep 13, 2022 20:04 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionStock Option (Right to Buy) · Derivative | 16,136 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001209191-22-049681 · doc4.xml · derivative · entry 8 Fordyce Marshall · CIK 0001859453 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,001,575 Underlying: Class A Common Stock · 16,136 shares Expires 2030-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| September 12, 2022 Filed Sep 13, 2022 20:04 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 3,315 | $21.07 | $69,846.39 |
DisclosureSEC source: 0001209191-22-049681 · doc4.xml · nonDerivative · entry 6 Fordyce Marshall · CIK 0001859453 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,150 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 9, 2022. F4 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $21.02 to $21.18, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 12, 2022 Filed Sep 13, 2022 20:04 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 3,315 | $2.90 | $9,602.89 |
DisclosureSEC source: 0001209191-22-049681 · doc4.xml · nonDerivative · entry 5 Fordyce Marshall · CIK 0001859453 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,465 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 12, 2022 Filed Sep 13, 2022 20:04 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 12,821 | $20.53 | $263,194.62 |
DisclosureSEC source: 0001209191-22-049681 · doc4.xml · nonDerivative · entry 4 Fordyce Marshall · CIK 0001859453 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,150 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 9, 2022. F3 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $20.01 to $21.01, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.